药师驱动的FDA配制药物事件监测与响应计划
本文概述《联邦食品、药品和化妆品法案》503A与503B条款下的药物配制,并介绍药师在FDA配制事件计划中的角色。该计划通过监测、审评和响应不良事件与投诉,保护公众免受劣质配制药物危害。药师利用临床技能与法规知识review并处理影响公共健康的安全问题。
要点
- 配制药物可满足无法使用FDA批准药品患者的医疗需求,但未经FDA批准及上市前安全性、有效性或生产质量审评。
- 及时报告配制相关不良事件或投诉对识别风险和实施保护措施至关重要。
- FDA配制事件计划由药师团队负责监测审评不良事件与投诉,并采取后续行动。
核心结论
- 药师是FDA配制事件计划的重要组成部分,利用临床技能与法规知识review并处理影响公共健康的安全问题。
- 鼓励医疗专业人员和消费者继续通过FDA的MedWatch报告系统提交不良事件报告,外包设施也应遵守不良事件报告合规要求。
研究设计与样本
- 本文为综述,概述《联邦食品、药品和化妆品法案》503A和503B条款下的药物配制,并描述药师在FDA配制事件计划中的角色。
主要发现
- 配制药物未经FDA批准,不受上市前安全性、有效性或生产质量审评,可能对患者构成安全风险。
- FDA配制事件计划由药师团队 dedicated to 监测和审评不良事件与投诉,并针对配制药物相关安全风险采取后续行动。
临床怎么用
- 临床药师应关注配制药物相关不良事件,并及时通过MedWatch报告系统向FDA提交报告。
- 药师可利用临床技能与法规知识参与配制药物安全监测与响应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide an overview of compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and to describe the pharmacist's role within the US Food and Drug Administration's (FDA's) Compounding Incidents Program, whose efforts are aimed at protecting the public against poor-quality compounded drugs through surveillance, review and response to adverse events and complaints. SUMMARY: Compounded drugs may serve an important medical need for patients who cannot be treated with medications approved by FDA; however, compounded drugs are not approved by FDA and are not subject to premarket review for safety, efficacy, or manufacturing quality; thus, they may pose safety risks to patients. Prompt reporting of adverse events or complaints related to compounding is important in identifying these risks and implementing safeguards to protect the public. FDA's Compounding Incidents Program consists of a team of pharmacists dedicated to the surveillance and review of adverse events and complaints and follow-up actions related to safety risks associated with compounded drugs. Pharmacists are a vital component of FDA's Compounding Incidents Program, utilizing their clinical skill set and regulatory knowledge to review and act on safety issues that affect public health. CONCLUSION: As FDA continues to expand the Compounding Incidents Program and its efforts to protect the public against poor-quality compounded drugs, we encourage the continued submission of adverse event reports by healthcare professionals and consumers to FDA's MedWatch reporting system in addition to adverse event reporting compliance by outsourcing facilities.
引用
- Janusziewicz AN, Glueck SN, Park SY, et al. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs. Am J Health Syst Pharm. 2021. PMID: 33889929. doi:10.1093/ajhp/zxab176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。